Upstream Bio, Inc. UPB
Set alert
At close · Oct 30
After hours · Oct 30, 4:44 PM ET
- YTD
- -87.44%
- 1 year
- -86.77%
- Open
- 3.26
- Prev close
- 3.27
- Mkt cap
- 186.77M
- Vol
- 946.13K
- Avg vol
- 846.31K
- EPS
- -2.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.15
- High
- 3.43
- Forward P/E
- -2.45
- Beta
- 0.00
- Short ratio
- 2.45
- Inst. own
- 94.73%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.55
- 200-d avg
- 19.11
- 1y target
- 47.86
News
3 weeks ago defenseworld.net
Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
Keros Therapeutics (NASDAQ: KROS - Get Free Report) and Upstream Bio (NASDAQ: UPB - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two…
1 month ago marketwatch.com
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
1 month ago globenewswire.com
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy and maintains $36 price target.
2 months ago globenewswire.com
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each…
2 months ago gurufocus.com
Fannie Mae Announces Sale of Non-Performing Loans
Fannie Mae Announces Sale of Non-Performing Loans PR Newswire WASHINGTON, Aug. 19, 2026
-
2 months ago benzinga.com
JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9
JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.
-
2 months ago benzinga.com
Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25
Truist Securities analyst Danielle Brill maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $43 to $25.
2 months ago zacks.com
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.
-
2 months ago benzinga.com
Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate
Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. This is a 1.35 percent increase over losses of $(0.74)…
3 months ago zacks.com
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 months ago gurufocus.com
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction
Fannie Mae Announces the Results of its Thirty-sixth Reperforming Loan Sale Transaction PR Newswire WASHINGTON,
-
4 months ago benzinga.com
Reported Sunday, Upstream Bio Presents Phase 2 VIBRANT Data Showing 79% Of Verekitug-Treated CRSwNP Patients Achieved Clinically Meaningful Nasal Polyp Score Improvements Versus 24% On Placebo
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –– Majority of verekitug-treated…
4 months ago globenewswire.com
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –
4 months ago businesswire.com
KBRA Assigns Preliminary Ratings to OBX 2026-AHC2 Trust
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 65 classes of mortgage pass-through notes from OBX 2026-AHC2 Trust, a prime agency-eligible RMBS transaction…
-
4 months ago benzinga.com
JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8
JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral and lowers the price target from $35 to $8.
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
4 months ago seekingalpha.com
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
-
4 months ago benzinga.com
Upstream Bio to Present New Verekitug Data at EAACI 2026, Phase 2 Nasal Polyps Analysis Gets EAACI Oral Presentation
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data…
4 months ago globenewswire.com
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe…
-
5 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $36
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Price Target of $36.
5 months ago globenewswire.com
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe…
5 months ago seekingalpha.com
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy
I am initiating a Buy rating on Verekitug, the lead asset of Upstream Bio, a small-cap biotech trading at an enterprise value under $200M. Verekitug's quarterly dosing and differentiated TSLPR…
-
5 months ago benzinga.com
Upstream Bio Presents New Data From Phase 2 VIBRANT Trial Evaluating Verekitug In Participants With Chronic Rhinosinusitis With Nasal Polyps At ATS 2026 International Conference
– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and…
5 months ago globenewswire.com
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and…
-
5 months ago benzinga.com
Mizuho Maintains Outperform on Upstream Bio, Lowers Price Target to $50
Mizuho analyst Joseph Catanzaro maintains Upstream Bio (NASDAQ:UPB) with a Outperform and lowers the price target from $51 to $50.
5 months ago zacks.com
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $0.51 per share a year ago.
-
5 months ago benzinga.com
Upstream Bio Q1 EPS $(0.75) Beats $(0.77) Estimate, Sales $1.034M Beat $442.000K Estimate
Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.77) by 2.6 percent. This is a 47.06 percent decrease over losses of $(0.51)…
5 months ago globenewswire.com
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for…
-
6 months ago benzinga.com
Upstream Bio Announces Presentation Of New Data From Phase 2 VIBRANT Trial At American Thoracic Society Meeting On May 18
The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical…
6 months ago globenewswire.com
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe…
6 months ago benzinga.com
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker
Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermatitis study misses main goal.
-
7 months ago benzinga.com
Evercore ISI Group Downgrades Upstream Bio to In-Line, Lowers Price Target to $15
Evercore ISI Group analyst Cory Kasimov downgrades Upstream Bio (NASDAQ:UPB) from Outperform to In-Line and lowers the price target from $40 to $15.
7 months ago benzinga.com
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of public offerings. Other stocks also lower.
7 months ago 247wallst.com
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and the price of oil…
7 months ago benzinga.com
Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data
The company reported a cash position of $341.5 million, expected to fund planned operations through 2027.
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
1 year ago benzinga.com
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago benzinga.com
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket